PTC Therapeutics (PTCT) has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million upon the closing of the transaction. The company was granted the PRV on November 13, 2024 along with the FDA approval of KEBILIDI.
The FDA awards priority review vouchers to sponsors of rare pediatric disease product applications. A PRV can be redeemed to receive priority review of a subsequent marketing application for a different product, or it can be sold or transferred.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.